ABUS Explodes 9900% in Q1! Is This Biopharma Stock Your Next BIG Bet?
Could a small biopharma company turn a devastating $24.5 million loss into a stunning $169.7 million profit in just one year? Arbutus Biopharma Corporation, known by its NASDAQ ticker ABUS, recently shocked the market with a colossal revenue surge from $1.8 million to $179.1 million in Q1 2026, primarily due to a landmark litigation settlement with Moderna via Genevant Sciences. This dramatic financial turnaround was further bolstered by significant cost reductions, even as its imdusiran program received Fast Track designation from the US Food Food and Drug Administration, promising expedited development for crucial viral disease therapeutics. Despite its newfound strength, some analysts suggest even greater upside lies in specific AI stocks for savvy investors. Dive deeper into these market-moving stories and much more by subscribing to our channel today!
Tags/Hashtags: #abus #biopharma #investing #moderna #imdusiran #abus #moderna
Leave a Reply